Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report
Authors:
- 27 February 2023
- journal article
- case report
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 38 (4) , 275-280
Abstract
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have an antidepressant effect due to 5-HT7 as well as 5-HT2A and 5-HT1a receptor affinity. Here we present a case of a 19-year-old male patient with first-episode psychosis (FEP) and predominant depressive symptoms. Remarkable clinical and functional improvement was observed 3 months after the beginning of lurasidone treatment. The patient’s depressive symptoms disappear with a dramatic reduction of psychotic ones, with good tolerance of the drug and without adverse effects. Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms.Keywords
This publication has 20 references indexed in Scilit:
- Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studiesCNS Spectrums, 2014
- Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtypeNeuropharmacology, 2013
- The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up studyEuropean Psychiatry, 2012
- A comparison of adolescent- and adult-onset first-episode, non-affective psychosis: 2-year follow-upEuropean Archives of Psychiatry and Clinical Neuroscience, 2012
- Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Depression and Depressive Symptoms in First Episode PsychosisJournal of Nervous & Mental Disease, 2010
- Lurasidone: a new drug in development for schizophreniaExpert Opinion on Investigational Drugs, 2009
- 5-HT7 Receptor Antagonists as a New Class of AntidepressantsDrug News & Perspectives, 2007
- Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic AgentsAmerican Journal of Psychiatry, 2000
- A depression rating scale for schizophrenicsSchizophrenia Research, 1990